



7.30-04

TFW

**PATENT APPLICATION**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant(s): Elbaum et. al.

Serial No.: 10/823,809

Group Art Unit No.: 1614

Filed: April 12, 2004

Examiner: Not yet assigned

For: SUBSTITUTED ARYLAMINE DERIVATIVES AND METHODS OF USE

Docket No.: A-735C

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

As a means of complying with the duty of disclosure under 37 CFR 1.97 and 1.98, applicant(s) submit(s) a "List of References Cited by Applicant" on a modified PTO-1449 form.

Under the guidelines of 37 C.F.R. 1.97, applicants submit a copy of references B27 and B28, listed on the attached supplemental PTO-1449 (Modified) form for consideration by the Examiner.

In accordance with 37 CFR 1.98(d), copies of the patents, publications, pending U.S. applications, or other information listed in this information disclosure statement are not required to be provided and are not enclosed because they were previously cited by or submitted to the Office in prior application Serial No. 10/197,960, filed July 17, 2002. The present application is a continuation of this prior application which is relied upon for an earlier filing date under 35 USC 120 and the information disclosure statement submitted in the earlier application complies with 37 CFR 1.98(a)-(c).

The information disclosure statement submitted herewith is being filed within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, or before the mailing of a first Office action after the filing of a request for continued examination under section 1.114, whichever event occurs last. 37 CFR 1.97(b).

Applicant(s) request(s) consideration of this information and passage of the application to issue.

**EXPRESS MAIL CERTIFICATE**

"Express Mail" mail labeling number:

EV351338365US

Date of Deposit:

July 28, 2004

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.


DEBBIE LABASS  
Printed Name

*Debbie Labass*  
Signature

**PATENT APPLICATION**

The Commissioner is hereby authorized to charge any filing fees which may be required or credit any overpayment to Deposit Account No. 01-0519 in the name of Amgen Inc.

Respectfully submitted,



Joseph W. Bullock  
Attorney/Agent for Applicant(s)


Registration No.: 37,103

Phone: (805) 447-7966

Date: July 28, 2004

Please send all future correspondence to:

US Patent Operations/JWB  
Dept. 4300, M/S 27-4-A  
AMGEN INC.  
One Amgen Center Drive  
Thousand Oaks, California 91320-1799



Modified Form PTO-1449

Atty. Docket No.

A-735C

Serial No.

10/823,809

**LIST OF REFERENCES CITED BY APPLICANT**

(Use several sheets if necessary)

Applicant

Elbaum et al.

Filing Date

April 12, 2004

Group

1614

**U.S. PATENT DOCUMENTS**

EXAMINER'S INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
	A1	3,226,394	12/28/1965	Schipper et al.			
	A2	5,532,358	07/02/1996	Kelly			
	A3	6,140,351	10/31/2000	Arnaiz et al.			

**FOREIGN PATENT DOCUMENTS**

EXAMINER'S INITIALS		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION	
							YES	NO
	B1	DE 19830430	13 Jan 2000	Germany				
	B2	EP 0 947 500 A1	06 Oct 1999	Europe				
	B3	EP 1 219 609	3 Jul 2002	Europe			X	
	B4	FR 2 168 227	31 Aug 1973	France				X
	B5	JP 2000 256358	19 Sep 2000	Japan				X
	B6	WO 96/41795	27 Dec 1996	PCT				
	B7	WO 98/24771	11 Jun 1998	PCT				
	B8	WO 98/45268	15 Oct 1998	PCT				
	B9	WO 99/32477	01 Jul 1999	PCT				
	B10	WO 99/62885	09 Dec 1999	PCT				
	B11	WO 00/02851	20 Jan 2000	PCT				
	B12	WO 00/27819	18 May 2000	PCT				
	B13	WO 00/27820	18 May 2000	PCT				
	B14	WO 00/39111	06 Jul 2000	PCT				
	B15	WO 00/39117	06 Jul 2000	PCT				
	B16	WO 01/29009 A1	26 Apr 2001	PCT				
	B17	WO 01/30745 A1	03 May 2001	PCT				
	B18	WO 01/55114 A1	02 Aug 2001	PCT				
	B19	WO 01/55115 A1	02 Aug 2001	PCT				
	B20	WO 01/81311 A1	01 Nov 2001	PCT				

EXAMINER:

Date Considered:

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Modified Form PTO-1449	Atty. Docket No.	Serial No.
	A-735C	10/823,809
	Applicant	
	Elbaum et al.	
<b>LIST OF REFERENCES CITED BY APPLICANT</b> (Use several sheets if necessary)	Filing Date	Group
	April 12, 2004	1614

### U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
	B21	WO 01/85671 A2	15 Nov 2001	PCT		
	B22	WO 01/85691 A1	15 Nov 2001	PCT		
	B23	WO 01/85715 A2	15 Nov 2001	PCT		
	B24	WO 02/055501	18 Jul 2002	PCT		
	B25	WO 02/064546	22 Aug 2002	PCT		
	B26	WO 03/024935	27 Mar 2003	PCT		
	B27	WO 02/66470	29 Aug 2002	PCT		
	B28	WO 02/68406	6 Sep 2002	PCT		

EXAMINER'S INITIALS

### OTHER DOCUMENTS (Including Publisher, Author, Title, Date, Pertinent Pages, Etc.)

C1	Auerbach et al., "Angiogenesis Inhibition: A Review", Pharm. Ther., 63:265-311 (1994).
C2	Bagley et al., "Endothelial Precursor Cells as a Model of Tumor Endothelium: Characterization and Comparison with Mature Endothelial Cells", Cancer Research, 63:5866-5873 (2003).
C3	Bennett & Plum, editors., Cecil Textbook of Medicine, W.B. Saunders Co., 1004-1010 (1996).
C4	Breier et al., "The Role of Vascular Endothelial Growth Factor in Blood Vessel Formation", Trends in Cell Biology, 6:454-456 (1996).
C5	Carmeliet, P., "Mechanisms of Angiogenesis and Arteriogenesis", Nature Med., 6:389-395 (2000).
C6	Chemical Abstract DN 132:93104, also cited as WO 00/02851.
C7	Connell et al., "Patent Focus on Cancer Chemotherapeutics. II Angiogenesis Agents: April 2000 – September 2000", Exp. Opin. Ther. Patents, 11:77-114 (2001).
C8	Heinisch et al., "Pyridazines 89 <sup>1</sup> on the Synthesis of Novel 1,2-Diazine Containing Tricyclic Systems: Preparation of Dipyrizidinodiazepinones", Heterocycles, 51(5):1035-1050 (1999).
C9	Hennequin et al., "Design and Structure-Activity Relationship of a New Class of Potent VEGF Receptor Tyrosine Kinase Inhibitors", J. Med. Chem., 42:5369-5389 (1999).
C10	Konshin et al., "Synthesis and Antimicrobial Activity of Arylamides of N-(4-pyridyl)anthranilic acid", Chem. Abstr., 97:109837 (1981).

EXAMINER:

Date Considered:

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>Modified Form PTO-1449</b>  <b>LIST OF REFERENCES CITED BY APPLICANT</b>  (Use several sheets if necessary)	Atty. Docket No.	Serial No.
	A-735C	10/823,809
	Applicant	
	Elbaum et al.	
	Filing Date	Group
	April 12, 2004	1614

EXAMINER'S  
INITIALS**OTHER DOCUMENTS (Including Publisher, Author, Title, Date, Pertinent Pages, Etc.)**

C11	Leek, R.D., "The Prognostic Role of Angiogenesis in Breast Cancer", Anticancer Res., 21:4325-4332 (2001).
C12	Mehta et al., "Independent Association of Angiogenesis Index with Outcome in Prostate Cancer", Clin. Cancer Res., 7:81-88 (2001).
C13	Papamichael, D., "Prognostic Role of Angiogenesis in Colorectal Cancer", Anticancer Res., 21:4349-4354 (2001).
C14	Scappaticci, F.A., "Mechanisms and Future Directions for Angiogenesis-Based Cancer Therapies", J. Clin. Onc., 20:3906-3927 (2002).
C15	Seto et al., "Molecular Self-Assembly Through Hydrogen Bonding: Supramolecular Aggregates Based on the Cyanuric Acid Melamine Lattice.", J. Amer. Chem. Soc., 115:905-916 (1993).
C16	Singh et al., "Substituted Imidazolines and their CNS Activity", Ind. J. Het. Chem., 2:129-132 (1992).
C17	Stewart et al., "The Angiogenic Receptor KDR is Widely Distributed in Human Tissues and Tumours and Relocates Intracellularly on Phosphorylation. An Immunohistochemical Study", Histopathology, 43:33-39 (2003).
C18	Uckun et al., "Current Cancer Drug Targets", Structure Based Design of Novel Anti-Cancer Agents, 1:59-71 (2001).
C19	Wang et al., "Homeostatic Modulation of Cell Surface KDR and Flt1 Expression and Expression of the Vascular Endothelial Cell Growth Factor (VEGF) Receptor mRNAs by VEGF", J. Biol. Chem., 275(21):15905-15911 (2000).
C20	Wang et al., "Expression and Endocytosis of VEGF and Its Receptors in Human Colonic Vascular Endothelial Cells", Am. J. Physiol. Gastrointest. Liver Physiol., 282:G1088-G1096 (2002).
C21	Zhmurenko et al., "Fiziologicheski Aktivnye Veshchestva", 8:89-92 (1976), also cited as Chem. Abstract DN 86:171214.

EXAMINER:

Date Considered:

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.